HDAC2 and asthma: According to Bi et al. 2020, inhibiting the PI3K-Akt signaling pathway with PI3K inhibitors mitigates glucocorticoid (GC) insensitivity in severe asthma by restoring HDAC2 activity and inhibiting the phosphorylation of nuclear signaling transcription factors [40].